amenable to treatment. This hope is based on a paradigm attributed to William Stewart Halsted, which holds that cancer arises at a single location, grows there, and even tually migrates to local lymph nodes and then to more distant organs. If the Halstedian para digm is correct, effective screen ing should allow cancers destined to metastasize to be identified at an earlier stage and reduce the in cidence of cancers that first pre sent as metastatic disease. Such a stage shift is typically viewed as necessary but not sufficient to en able screening to reduce mortality.
We considered two cancersbreast and prostate -for which screening has been particularly prominent. The Surveillance, Epi demiology, and End Results (SEER) program provides data on the in cidence of metastatic cancer -a metric that includes only cases in which cancer is first diagnosed when a patient presents with me tastases, not those in which early stage cancer is diagnosed and then progresses to metastatic dis ease. The incidence of metastatic breast cancer has been stable since 1975 (see graph). In contrast, the incidence of metastatic prostate cancer has decreased by half since 1988. Although SEER data aren't available for earlier years, data from the Seattle-Puget Sound registry suggest that the incidence of metastatic prostate cancer was stable before 1988. 1 What explains these discordant trends? The stable incidence of metastatic breast cancer suggests two things. First, the underlying probability of developing this form of breast cancer is itself stable. Second, screening mam mography has been unable to identify at an earlier stage, be fore symptoms appear, cancers that are destined to become meta static. In fact, the mean age at diagnosis among women 40 years of age or older hasn't changed over the past 37 years, remaining at 63.7 years. Either mammogra phy isn't sensitive enough to iden tify these cancers early or they don't fit the Halstedian paradigm of steady progression. The lack of change in the incidence of meta static disease is consistent with the hypothesis that breast cancer is a systemic disease by the time it's detectable -a paradigm typi cally attributed to Bernard Fisher. In contrast, the steep decline in the incidence of metastatic Although these discordant trends could reflect distinct dis ease dynamics, they could also be the result of different screen ing strategies. Mammography rep resents an anatomical search for a structural abnormality; PSA screening uses a biochemical as say to detect a tumor marker. It's possible that the latter is a much more sensitive indicator of dis ease burden. Were a similar breastcancer assay discoveredand a similar organwide sam pling strategy used (the typical prostate biopsy now involves at least 10 needle cores throughout the organ) -then perhaps fewer women would present with meta static breast cancer. Again, wheth er mortality would therefore de cline is a separate question.
Samuel Hellman proposed a third paradigm: that for each type of cancer there are multiple paths to metastasis. 4 Aggressive, poorly differentiated cancers tend toward the Fisher paradigm; localized, welldifferentiated cancers tend toward that of Halsted. There's evidence of such variability in breast cancer. Whereas breast can cers destined to present as meta static disease have not been ame nable to earlydetection efforts, metastatic progression from dis ease that is local or regional at presentation can be detected ear lier than it once was -albeit with no change in the risk of death. 5 Earlier diagnosis may be possible for women with cancers that would ultimately become metastatic -but not for some women presenting with metasta ses -because the two groups have different disease dynamics.
Although prostate cancer may in general be a slowly progress ing disease that allows ample time for early detection, there is also evidence of variability. The incidence of metastatic prostate cancer has stabilized during the past decade at a rate similar to that seen in breast cancer. This finding suggests a similarity be tween the two diseases: both appear to include a subgroup of cases that first present as a sys temic disease. Because early detection efforts will never be successful for patients with such cases, disease dynamics can have a profound effect on the efficacy of screening.
Given the increasing enthusi asm for genomic, proteomic, and immunosignature testing to en hance early cancer detection, we be lieve it will be crit ical to consider the variability in cancer dynamics. Some cancers will be systemic at the outset, some will progress and some will not. Conflating these types of lesions could re sult in screening programs that are not helpful and administra tion of treatment that is either not needed or not effective. As Hellman concluded two decades ago, "The lesson from all this is the value of clinical investigation to study the natural history of disease." T he Internal Revenue Service (IRS) recently finalized new requirements for nonprofit hospi tals to maintain their taxexempt status under the Affordable Care Act (ACA). 1 Section 501(r) of the Internal Revenue Code now re quires each hospital to establish a written financialassistance pol icy that applies to all "emergency and medically necessary care." Through these policies, hospitals must strive to ensure that patients who qualify for fully or partially subsidized charity care can apply for and receive it, are charged reasonable amounts, and are not subject to extraordinary billcol lection practices when they have outstanding medical debt. Hos pitals are also required to assess the health needs of their com munity every 3 years. Failure to comply with Section 501(r) could result in a $50,000 excise tax, losing taxexempt status, or both, once the requirements are fully implemented in 2016. 1 Section 501(r) arose from long standing concerns over whether nonprofit hospitals provide suffi cient community benefits -and specifically charity care -to justify their taxexempt status, valued at $24.6 billion in 2011. 2 Key policymakers, such as Senator Charles Grassley (RIA), believe that some nonprofit hospitals provide insufficient charity care and use "extremely punitive" mea sures to collect unpaid medical bills from lowincome patients. 3 A 2013 study by Young and col leagues showed that charity care represented only 2% of hospital operating expenses on average, or roughly a quarter of total expen ditures on community benefits. 4 After unsuccessful attempts to re quire nonprofit hospitals to spend at least 5% of revenues on charity care, 5 the architects of Section 501(r) envisioned greater over sight in increasing the provision of charity care. Measured against these hopes, the effect of the new requirement on charity care is likely to be mixed.
Policymakers, hospital leaders, and practicing physicians face key questions about Section 501(r). How have hospitals responded to the requirements, which became effective when the ACA was en acted? How will compliance with the new requirements affect the provision of charity care, and how will its effects differ between states that have chosen to expand Medicaid under the ACA and those that have chosen not to? Although the ACA should greatly 
